Patents by Inventor Stephen Martin

Stephen Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
    Patent number: 8536186
    Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: September 17, 2013
    Assignee: CHDI Foundation, Inc.
    Inventors: John Wityak, Leticia M. Toledo-Sherman, Celia Dominguez, Stephen Martin Courtney, Christopher John Yarnold, Paula C. De Aguiar Pena, Andreas Scheel, Dirk Winkler
  • POLYMER TREATMENT METHOD
    Publication number: 20130167882
    Abstract: The invention provides a method for the treatment of polymeric particles recovered after use in cleaning processes for soiled substrates, the method comprising treating the particles with a particle cleaning agent. Preferably, said agent comprises at least one surfactant. Preferably said agent comprises an aqueous medium. Typically, the polymeric particles comprise particles of nylon or polyester. The invention also provides a method for cleaning a soiled substrate, the method comprising the steps of: (a) treating polymeric particles with a particle cleaning agent; and (b) treating a moistened substrate with a formulation comprising a multiplicity of said treated polymeric particles. Most preferably, the substrate comprises a textile fibre or fabric.
    Type: Application
    Filed: September 14, 2011
    Publication date: July 4, 2013
    Applicant: XEROS LIMITED
    Inventors: Stephen Martin Burkinshaw, Stephen Derek Jenkins, Frazer John Kennedy, John Edward Steele
  • TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20130116216
    Abstract: Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.
    Type: Application
    Filed: November 12, 2010
    Publication date: May 9, 2013
    Inventors: Celia Dominguez, John Wityak, Michael Prime, Stephen Martin Courtney, Christopher Yarnold, Frederick Brookfield, Richard Marston, Douglas Macdonald
  • Microelectromechanical systems microphone packaging systems
    Patent number: 8421168
    Abstract: This document discusses, among other things, a conductive frame, a silicon die coupled to the conductive frame, the silicon die including a vibratory diaphragm, the die having a silicon die top opposite a silicon die bottom, with a silicon die port extending through the silicon die to the vibratory diaphragm, with a silicon die terminal in electrical communication with the conductive frame and an insulator affixed to the conductive frame and the silicon die, with the insulator extending through interstices in the conductive frame to a conductive frame bottom of the conductive frame, and around an exterior of the silicon die to the silicon die top, with the insulator physically affixed to the silicon die and to the conductive frame, with the silicon die port exposed and with a conductive frame terminal disposed at the conductive frame bottom in electrical communication with the silicon die terminal.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: April 16, 2013
    Assignee: Fairchild Semiconductor Corporation
    Inventors: Howard Allen, Luke England, Douglas Alan Hawks, Yong Liu, Stephen Martin
  • SEAL SUPPORT SYSTEM PRESSURE TRACKING VALUE
    Publication number: 20130048108
    Abstract: A pressure regulation tracking valve for maintaining the pressure of a gas relative to that of a process fluid includes a device, responsive to change in the pressure of the process fluid, for changing the pressure of the gas by substantially the same amount. The valve further includes a device for accommodating a pressure transfer medium for transferring the pressure of the process fluid to the gas pressure changing device. As a result, contact between the process fluid and the gas pressure changing device is avoided.
    Type: Application
    Filed: April 26, 2011
    Publication date: February 28, 2013
    Inventors: Christopher John Carmody, Stephen Martin Shaw, Andrew John Stoney
  • CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20120329812
    Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
    Type: Application
    Filed: August 3, 2009
    Publication date: December 27, 2012
    Inventors: John Wityak, Leticia M. Toledo-Sherman, Celia Dominguez, Stephen Martin Courtney, Christopher John Yarnold, Paula C. De Aguiar Pena, Andreas Scheel, Dirk Winkler
  • TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20120302539
    Abstract: Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.
    Type: Application
    Filed: May 7, 2012
    Publication date: November 29, 2012
    Inventors: Michael Prime, Stephen Martin Courtney, Richard Marston, Celia Dominguez, Douglas Macdonald, John Wityak
  • N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS
    Publication number: 20120258965
    Abstract: The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxylsulfonamide derivatives.
    Type: Application
    Filed: June 22, 2012
    Publication date: October 11, 2012
    Applicants: The Johns Hopkins University, Cardioxyl Pharmaceuticals
    Inventors: John P. TOSCANO, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish
  • MODULAR SEAL SUPPORT SYSTEM
    Publication number: 20120235358
    Abstract: A seal support system, or a kit therefor, for use with a sealing device to seal a piece of industrial equipment, includes a stand with fixed support elements for accommodating selected functional components with different sizes of components being accommodated by differently sized pipework elements. The stand has one or more substantially fixed brackets with each bracket having a component securing device at predetermined longitudinal space intervals.
    Type: Application
    Filed: April 29, 2010
    Publication date: September 20, 2012
    Inventors: Christopher John Rea, Stephen Martin Shaw, Andrew Colverson, Alan James Roddis
  • N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
    Patent number: 8227639
    Abstract: The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxylsulfonamide derivatives.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: July 24, 2012
    Assignees: Cardioxyl Pharmaceuticals, The Johns Hopkins University
    Inventors: John P. Toscano, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish
  • ANTIGEN-BINDING PROTEINS
    Publication number: 20120177651
    Abstract: The invention relates to combinations of HGF antagonists with VEGF antagonists, and provides antigen-binding proteins which bind to HGF comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding protein has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof.
    Type: Application
    Filed: May 26, 2010
    Publication date: July 12, 2012
    Inventors: Neil James Clarke, Susannah Karen Ford, Paul Andrew Hamblin, Stephen Martin
  • Wafer level stack die package
    Patent number: 8211747
    Abstract: This document discusses, among other things, apparatus and methods for an IC package including first and a second discrete components fabricated into a semiconductor substrate. The first and second discrete components can be adjacent to one another in the semiconductor substrate, and an integrated circuit die can be mounted on the semiconductor substrate and coupled to the first and second discrete components.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: July 3, 2012
    Assignee: Fairchild Semiconductor Corporation
    Inventors: Dan Kinzer, Yong Liu, Stephen Martin
  • WAFER LEVEL STACK DIE PACKAGE
    Publication number: 20120088331
    Abstract: This document discusses, among other things, apparatus and methods for an IC package including first and a second discrete components fabricated into a semiconductor substrate. The first and second discrete components can be adjacent to one another in the semiconductor substrate, and an integrated circuit die can be mounted on the semiconductor substrate and coupled to the first and second discrete components.
    Type: Application
    Filed: December 13, 2011
    Publication date: April 12, 2012
    Inventors: Dan Kinzer, Yong Liu, Stephen Martin
  • BIOMARKERS AND USES THEREOF
    Publication number: 20120064100
    Abstract: The present invention provides markers of regulatory T (Treg) cells, preferably, cell surface markers of Treg cells and uses of those markers or compounds that bind thereto to identify or isolate Treg cells or to diagnose/prognose/treat/prevent Treg-mediated conditions. The present invention also provides methods for identification and/or isolation of Treg cell subpopulations and such isolated subpopulations of Treg cells.
    Type: Application
    Filed: March 18, 2010
    Publication date: March 15, 2012
    Inventors: Simon Barry, Timothy John Sadlon, Stephen Martin Pederson, Bridget Gabrielle Wilkinson, Doreen Krumbiegel, Ian Cameron Nicholson, Heddy Zola
  • Pyridine derivatives
    Patent number: 8134007
    Abstract: The present invention relates to compounds of the formula (I): and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: March 13, 2012
    Assignee: Pfizer Inc.
    Inventors: Sharanjeet Kaur Bagal, Karl Richard Gibson, Mark Ian Kemp, Cedric Poinsard, Blanda Luzia Stammen, Stephen Martin Denton, Melanie Susanne Glossop
  • Wafer level stack die package
    Patent number: 8115260
    Abstract: This document discusses, among other things, an IC package including first and a second discrete components fabricated into a semiconductor substrate. The first and second discrete components can be adjacent to one another in the semiconductor substrate, and an integrated circuit die can be mounted on the semiconductor substrate and coupled to the first and second discrete components.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: February 14, 2012
    Assignee: Fairchild Semiconductor Corporation
    Inventors: Dan Kinzer, Yong Liu, Stephen Martin
  • N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors
    Publication number: 20110306614
    Abstract: The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.
    Type: Application
    Filed: August 19, 2011
    Publication date: December 15, 2011
    Applicants: THE JOHNS HOPKINS UNIVERSITY, CARDIOXYL PHARMACEUTICALS, INC.
    Inventors: John P. Toscano, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish
  • N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
    Patent number: 8030356
    Abstract: The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: October 4, 2011
    Assignees: Cardioxyl Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: John P. Toscano, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish
  • CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20110230428
    Abstract: Certain chemical entities are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
    Type: Application
    Filed: July 22, 2009
    Publication date: September 22, 2011
    Inventors: John Wityak, Leticia M. Toledo-sherman, Celia Dominguez, Stephen Martin Courtney, Christopher John Yarnold, Paula C. De Aguiar Pena, Andreas Scheel, Dirk Winkler
  • CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20110183957
    Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
    Type: Application
    Filed: August 4, 2009
    Publication date: July 28, 2011
    Inventors: John Wityak, Leticia M. Toledo-Sherman, Celia Dominguez, Stephen Martin Courtney, Christopher John Yarnold, Paula C. De Aguiar Pena, Andreas Scheel, Dirk Winkler